Could a diabetes drug curb Binge-Eating? new trial aims to find out
NCT ID NCT06847399
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether the drug tirzepatide can help adults with obesity and binge-eating disorder reduce binge episodes and lose weight. It compares tirzepatide to a placebo and to another drug, lisdexamfetamine dimesylate. All 105 participants will also receive guided self-help therapy. The trial lasts 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21146, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirzepatide
What this could lead to
If successful, tirzepatide could offer a new treatment option for binge-eating disorder that also helps with weight loss.
What could go wrong
This is an early Phase 2 trial with only 105 people, so results may not apply broadly. Tirzepatide may cause side effects like nausea or vomiting, and it's not yet proven to work for binge-eating disorder.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.